Loading
A treatment that adds two months of life but takes up most of those days in hospitals and clinics may not be worth it to an older patient. Trials should report how many days treatment consumes.
Time toxicity, the number of days with physical healthcare contact, has been proposed as a patient-relevant outcome that is easily measurable from trial and administrative data. For older patients with limited survival, it may outweigh modest survival gains. Requiring its reporting in trials and in real-world evaluations of new therapies would inform shared decisions and could change the perceived value of some regimens.
Shares Progression-free survival (PFS), Overall survival (OS), Trial design, endpoints and cost, Toxicity and quality of life are undervalued.
Shares Progression-free survival (PFS), Overall survival (OS), Toxicity and quality of life are undervalued.
Shares Progression-free survival (PFS), Overall survival (OS), Trial design, endpoints and cost.
Shares Progression-free survival (PFS), Trial design, endpoints and cost, Toxicity and quality of life are undervalued.
Shares Progression-free survival (PFS), Overall survival (OS), Trial design, endpoints and cost, Toxicity and quality of life are undervalued.
Shares Older and multimorbid patients are excluded and undertreated, Trial design, endpoints and cost.
Shares Older and multimorbid patients are excluded and undertreated, Trial design, endpoints and cost.
Shares Overall survival (OS), Trial design, endpoints and cost.